(Q45111985)

English

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

scientific article published on 9 May 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

phase III clinical trial

0 references

1 reference

ChEBI release 2020-05-28

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jie Jin

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Jian-Xiang Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Fei-Fei Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

De-Pei Wu

4

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Jiong Hu

5

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Jian-Feng Zhou

6

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Jian-Da Hu

7

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Jian-Min Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Jian-Yong Li

9

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Xiao-Jun Huang

10

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Jun Ma

11

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Chun-Yan Ji

12

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Xiao-Ping Xu

13

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Kang Yu

14

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Han-Yun Ren

15

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Yu-Hong Zhou

16

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Yin Tong

17

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Yin-Jun Lou

18

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Wan-Mao Ni

19

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Hong-Yan Tong

20

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Hua-Feng Wang

21

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Ying-Chang Mi

22

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Xin Du

23

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Bao-An Chen

24

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Yi Shen

25

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Zhu Chen

26

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Sai-Juan Chen

27

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

publication date

9 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

599-608

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Anthracycline dose intensification in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

DAE (daunorubicin, Ara-C, and etoposide) and intermediate dose Ara-C for remission induction and consolidation treatment of adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970152-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70152-9

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45111985&oldid=2066256225"